FDA Approved New Treatment for Rare Bone Condition

Patients with fibrodysplasia ossificans progressiva aged 12 and older now have a new, once-daily oral medication option.

Updated on Sept. 26, 2026 in Diseases — General

Isometric editorial illustration showing a set of smooth pharmaceutical capsules beside a geometric lattice structure, representing medical development. — The U.S. Food and Drug Administration has approved Atebrioz, a new daily oral medication for individuals 12 and older with the rare bone condition fibrodysplasia ossificans progressiva. AI Illustration. Upload story photo >

Live Poll

Should the FDA prioritize expanding access to new medical treatments for younger patients?

The US FDA has approved Atebrioz, a new once-daily pill for individuals 12 years and older living with fibrodysplasia ossificans progressiva. This rare, chronic condition causes muscles, tendons, and ligaments to gradually harden into bone.

Why it matters

This approval provides a new treatment pathway for managing the progression of this debilitating condition. While the drug is now cleared for use, patients should discuss its potential role in their care plan with a specialized physician.

The FDA granted approval for Atebrioz based on evidence supporting its use for patients 12 years and older. The medication is intended to slow the progression of bone-forming tissue hardening, though clinicians are still evaluating its long-term benefits for patients.

The players

FDA

The federal agency responsible for evaluating and authorizing the safety and efficacy of new pharmaceuticals in the United States.

Mirum Pharmaceuticals

The manufacturer of Atebrioz that specializes in developing novel therapies for rare and orphan diseases.

The details

Atebrioz is a once-daily oral medication designed to interfere with the biological processes that cause soft tissues like muscles, tendons, and ligaments to calcify. By targeting these pathways, the drug works to slow the hardening of tissues characteristic of fibrodysplasia ossificans progressiva. Patients and their caregivers should consult a specialist to understand how this therapy integrates into existing management strategies.

September 25, 2026: The FDA officially approved Atebrioz for public use.

Cancer
Sept. 18
New Breast Cancer Drug Combo Doubled Survival
Cancer
Sept. 23
FDA Granted Special Status to New Cancer Drug SOT106
Asthma
Sept. 24
FDA Agreed on Phase 3 Protocol for Sarcoidosis Drug

Health Landscape

This approval follows the FDA Orphan Drug Designation program, which facilitates the development of therapies for rare diseases affecting small patient populations. It marks a shift in the treatment landscape for a condition that previously lacked specialized therapeutic options.

If you or a family member are living with this condition, consider raising the availability of Atebrioz with your specialist during your next checkup. Your physician can help determine if this new once-daily treatment is appropriate based on your specific health history.

The takeaway

This new medication offers a novel approach to slowing the tissue hardening associated with this rare disease. Individuals should work with their specialized care team to monitor for symptoms of progression and discuss the potential benefits of this new FDA-authorized treatment.